CSIMarket
 



Jounce Therapeutics inc   (JNCE)
Other Ticker:  
 
 



 

What are Jounce Therapeutics Inc's Business Segments?



Jounce Therapeutics Inc is a clinical stage biotechnology company founded in 2013 and headquartered in Cambridge, Massachusetts. The company specializes in the discovery and development of immunotherapies for the treatment of cancer. Their platform technologies leverage advances in understanding the biology of the immune system and the tumor microenvironment to develop novel cancer immunotherapies.

Segments:

Jounce Therapeutics Inc is a biotechnology company that operates within the healthcare industry, specifically within the global oncology market. To date, Jounce has not diversified into other healthcare sectors, and its business remains concentrated on bringing innovative cancer immunotherapies to market. The company operates in a highly specialized segment of the oncology market, focusing on the development of immunotherapies that target immune-altering mechanisms in cancer cells.

Products:

Jounce Therapeuticse has a product pipeline that comprises both clinical and preclinical development candidates. All of the companyes product candidates are designed to activate immune cells to attack specific cancer cells. The company has two primary product candidates that are currently in development:

1. JTX-8064: JTX-8064 is a monoclonal antibody designed to activate immune cells in the tumor microenvironment. It is currently being studied in a Phase 1 clinical trial to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors.

2. Vopratelimab: Vopratelimab is a monoclonal antibody designed to activate T cells in the tumor microenvironment. It is currently being studied in a Phase 2 clinical trial in combination with nivolumab, a checkpoint inhibitor, to evaluate its safety, tolerability, and efficacy in patients with non-small-cell lung cancer.

In addition to its primary product candidates, Jounce Therapeutics has a number of preclinical candidates in development that are designed to target specific mechanisms involved in the immune response to cancer.

Services:

Jounce Therapeutics offers a range of in-house services to support its product development pipeline. These services include:

1. Biomarker discovery: Jounce uses state-of-the-art technologies to identify biomarkers that may be predictive of response to its product candidates. This helps to inform patient selection and optimize dosing strategies.

2. Drug discovery and development: Jounce has a team of experienced scientists and researchers focused on drug discovery and development. The companyes platform technologies include high-throughput screening, bioinformatics, and proteomics to identify and validate new targets for cancer immunotherapy.

3. Clinical trial management: Jounce Therapeutics manages clinical trials in-house, from study design to patient enrollment and data analysis. The company has experience conducting both Phase 1 and Phase 2 clinical trials, and is focused on developing novel combination therapies that will help to improve patient outcomes.
   

Jounce Therapeutics Inc Tax Rate Companies within the Biotechnology & Pharmaceuticals Industry



To get more information on Jounce Therapeutics Inc's segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com